Research Topics
Species | L A EmensSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cancer vaccines in combination with multimodality therapyLeisha A Emens
The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231-1000, USA
Cancer Treat Res 123:227-45. 2005
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockadeLeisha A Emens
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Expert Rev Anticancer Ther 12:1597-611. 2012..Integrative breast cancer immunotherapies that strategically combine established breast cancer therapies with breast cancer vaccines, immune checkpoint blockade or both should result in durable clinical responses and increased cures...- Re-purposing cancer therapeutics for breast cancer immunotherapyLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
Cancer Immunol Immunother 61:1299-305. 2012.... 
Toward integrative cancer immunotherapy: targeting the tumor microenvironmentLeisha A Emens
Tumor Immunology and Breast Cancer Research Programs, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Transl Med 10:70. 2012....- Breast cancer vaccines: maximizing cancer treatment by tapping into host immunityL A Emens
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
Endocr Relat Cancer 12:1-17. 2005.... - Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancerLeisha A Emens
Tumor Immunology and Breast Cancer Research Programs, Sidney Kimmel Comprehensive Cancer Center, Baltimore 21231 1000, Maryland, USA
Am J Ther 12:243-53. 2005..This review summarizes the available clinical data on the use of trastuzumab in HER-neu-overexpressing breast cancer and briefly highlights emerging opportunities for innovative, trastuzumab-based breast cancer therapies... - Leveraging the activity of tumor vaccines with cytotoxic chemotherapyLeisha A Emens
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
Cancer Res 65:8059-64. 2005.... - Towards a therapeutic breast cancer vaccine: the next stepsLeisha A Emens
Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, MD 21231 1000, USA
Expert Rev Vaccines 4:831-41. 2005.... - Roadmap to a better therapeutic tumor vaccineLeisha A Emens
Department of Oncology, Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
Int Rev Immunol 25:415-43. 2006..The first of these combinatorial trials have already been reported and offer a tantalizing glimpse of the future of cancer immunotherapy... - Chemotherapy and tumor immunity: an unexpected collaborationLeisha A Emens
Department of Oncology, The Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, Room 4M90, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Front Biosci 13:249-57. 2008..Chemotherapy can be used with tumor vaccines in unexpected ways, breaking down these barriers and unleashing the full potential of the antitumor immune response... - Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Clin Oncol 27:5911-8. 2009..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer... - GM-CSF-secreting vaccines for solid tumorsLeisha A Emens
The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Curr Opin Investig Drugs 10:1315-24. 2009.... - ChemoimmunotherapyLeisha A Emens
Department of Oncology, The Johns Hopkins University, 1650 Orleans St, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Cancer J 16:295-303. 2010.... - Augmenting the potency of breast cancer vaccines: combined modality immunotherapyLeisha A Emens
Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
Breast Dis 20:13-24. 2004..Combined modality immunotherapies should maximize the potency of the antitumor immune response, thereby improving the outcome of breast cancer therapy... - Survivin' cancerLeisha A Emens
The Sidney Kimmel Comprehensive Cancer Center, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231-1000, USA
Cancer Biol Ther 3:180-3. 2004 - A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancerLeisha A Emens
Johns Hopkins Oncology Center, Baltimore, MD, USA
Breast Cancer Res Treat 76:145-56. 2002..Our aims were to determine the maximum tolerated dose (MTD) of 5-FU in the dose-dense regimen and to determine the impact of dose-dense chemotherapy on HDC/PBSCT... - A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicinLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-2410, USA
Hum Gene Ther 15:313-37. 2004 - Toward a breast cancer vaccine: work in progressLeisha A Emens
Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Oncology (Williston Park) 17:1200-11; discussion 1214, 1217-8. 2003.... - Cancer vaccines: on the threshold of successLeisha A Emens
Johns Hopkins University, Tumor Immunology and Breast Cancer Research Programs, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Expert Opin Emerg Drugs 13:295-308. 2008..Additional advantages of cancer vaccines are exquisite specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory... - Cancer vaccines: an old idea comes of ageLeisha A Emens
Departments of Oncology, The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland 21231 1000, USA
Cancer Biol Ther 2:S161-8. 2003.... - A new twist on autologous cancer vaccinesLeisha A Emens
The Sidney Kimmel Comprehensive Cancer Center, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231-1000 USA
Cancer Biol Ther 2:161-3. 2003 - To live or not to live: that depends on GAGE?Leisha A Emens
Departments of Oncology, The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
Cancer Biol Ther 1:388-90. 2002 - The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumorsR T Reilly
Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Cancer Res 61:880-3. 2001..These data suggest that vaccines optimized to induce maximal T- and B-cell immunity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in vivo antitumor immunity... - Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized miceJ P Machiels
The Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Immunology, Baltimore, Maryland 21231, USA
Cancer Res 61:3689-97. 2001..These data provide the immunological rationale for testing immune-modulating doses of chemotherapy in combination with tumor vaccines in patients with cancer... - Chemotherapy: friend or foe to cancer vaccines?L A Emens
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
Curr Opin Mol Ther 3:77-84. 2001..These interactions will require thorough preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine... - Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceLukas W Pfannenstiel
Department of Oncology, Sidney Kimmel Cancer Center, Division of Immunology, Johns Hopkins University, USA
Cell Immunol 263:79-87. 2010..Finally, PTX treatment results in enhanced antigen-specific, IFN-gamma-secreting CD8(+) T cells in vivo. Thus, administration of PTX with a tumor vaccine improves T cell priming through enhanced maturation of DC... - Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?R T Reilly
Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
Curr Opin Investig Drugs 2:133-5. 2001..This article seeks to explore the notion that a vaccine designed to optimally activate both arms of the immune system may well generate an antitumor immune response greater than the sum of the two individual effector mechanisms alone... - HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe
Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
J Immunol 171:2161-9. 2003..Collectively, these observations suggest that similarly increased efficacy could be obtained by combining neu-targeted vaccination and neu-specific Abs such as trastuzumab (Herceptin) in patients with neu-expressing cancers... - A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 13:3951-9. 2007.... - Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini
Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Exp Med 201:1591-602. 2005.... - Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
Clin Breast Cancer 10:40-5. 2010..We evaluated pathologic complete response (pCR) rate and cardiac safety of preoperative doxorubicin and cyclophosphamide followed by a taxane with or without trastuzumab... - Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCsPeter S Kim
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
J Clin Invest 118:1700-11. 2008..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment... - Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facilityJ M Davis-Sproul
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA
Cytotherapy 7:46-56. 2005..These studies define a feasible, reproducible and cost-effective methodology for production of a GM-CSF-secreting breast cancer vaccine that is cGMP compliant... - Trastuzumab in breast cancerLeisha A Emens
Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine Baltimore, Maryland 21231-1000, USA
Oncology (Williston Park) 18:1117-28; discussion 1131-2, 1137-8. 2004..Here we review the clinical development of this novel agent, emphasizing the potential for therapeutic synergy when trastuzumab is combined with both standard chemotherapy and innovative molecularly targeted and biologic agents... - Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancerRichard C Zellars
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
J Clin Oncol 27:2816-22. 2009..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)... - OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigenSatoshi Murata
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 176:974-83. 2006..These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity... - GM-CSF-secreting vaccines for solid tumors: moving forwardRicha Gupta
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA
Discov Med 10:52-60. 2010.... - Cytokine gene-modified cell-based cancer vaccinesR Todd Reilly
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Methods Mol Med 69:233-57. 2002 - Adjuvant hormonal therapy for premenopausal women with breast cancerLeisha A Emens
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA
Clin Cancer Res 9:486S-94S. 2003.... - The follow-up of breast cancerLeisha A Emens
Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
Semin Oncol 30:338-48. 2003..Finally, we present an evidence-based approach to breast cancer surveillance after therapy that is consistent with several clinical practice guidelines, maximizing outcome and minimizing cost... - GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancersPilar Nava Parada
The Johns Hopkins University and the Sidney Kimmel, Comprehensive Cancer Center Department of Oncology, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Curr Opin Mol Ther 9:490-7. 2007..GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer... - Cancer vaccines: toward the next revolution in cancer therapyLeisha A Emens
Int Rev Immunol 25:259-68. 2006
Research Grants
- CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENTLeisha Emens; Fiscal Year: 2006..abstract_text> ..